Raloxifene is primarily prescribed for postmenopausal women who have osteoporosis or are at high risk of breast cancer. Its use in premenopausal women is not recommended. Epidemiological guidelines suggest that patient selection should be based on a comprehensive risk assessment, including BMD tests and breast cancer risk factors.
